These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17154507)

  • 1. In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors.
    Muller P; Lena G; Boilard E; Bezzine S; Lambeau G; Guichard G; Rognan D
    J Med Chem; 2006 Nov; 49(23):6768-78. PubMed ID: 17154507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,2,4-Oxadiazolidin-3,5-diones and 1,3,5-triazin-2,4,6-triones as cytosolic phospholipase A2alpha inhibitors.
    Gopalsamy A; Yang H; Ellingboe JW; McKew JC; Tam S; Joseph-McCarthy D; Zhang W; Shen M; Clark JD
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2978-81. PubMed ID: 16545564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,3,5-Triazepan-2,6-diones as conformationally constrained dipeptide mimetics. In silico guided identification of sPLA2 inhibitors.
    Guichard G; Léna G; Boeglin J; Muller P; Boilard E; Lambeau G; Rognan D; Didierjean C
    Adv Exp Med Biol; 2009; 611():201-2. PubMed ID: 19400159
    [No Abstract]   [Full Text] [Related]  

  • 4. RASSE: a new method for structure-based drug design.
    Luo Z; Wang R; Lai L
    J Chem Inf Comput Sci; 1996; 36(6):1187-94. PubMed ID: 8941995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and target identification of hymenialdisine analogs.
    Wan Y; Hur W; Cho CY; Liu Y; Adrian FJ; Lozach O; Bach S; Mayer T; Fabbro D; Meijer L; Gray NS
    Chem Biol; 2004 Feb; 11(2):247-59. PubMed ID: 15123286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent inhibitors of secretory phospholipase A2: synthesis and inhibitory activities of indolizine and indene derivatives.
    Hagishita S; Yamada M; Shirahase K; Okada T; Murakami Y; Ito Y; Matsuura T; Wada M; Kato T; Ueno M; Chikazawa Y; Yamada K; Ono T; Teshirogi I; Ohtani M
    J Med Chem; 1996 Sep; 39(19):3636-58. PubMed ID: 8809154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.
    Boyd HF; Flynn ST; Hickey DM; Ife RJ; Jones M; Leach CA; Macphee CH; Milliner KJ; Rawlings DA; Slingsby BP; Smith SA; Stansfield IG; Tew DG; Theobald CJ
    Bioorg Med Chem Lett; 2000 Feb; 10(4):395-8. PubMed ID: 10714508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as human chymase inhibitors using structure-based drug design.
    Tanaka T; Sugawara H; Maruoka H; Imajo S; Muto T
    Bioorg Med Chem; 2013 Jul; 21(14):4233-49. PubMed ID: 23719288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Synthesis of lipophilic keto acids by acylation of alkylbenzenes as potential inhibitors of phospholipase A2].
    Nuhn P; Radman M; Hermann A; Marx K
    Pharmazie; 1998 Dec; 53(12):825-9. PubMed ID: 10189306
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.
    Pruzanski W; Stefanski E; Vadas P; McNamara TF; Ramamurthy N; Golub LM
    J Rheumatol; 1998 Sep; 25(9):1807-12. PubMed ID: 9733464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformationally restricted (+)-cacospongionolide B analogues. Influence on secretory phospholipase A2 inhibition.
    Murelli RP; Cheung AK; Snapper ML
    J Org Chem; 2007 Mar; 72(5):1545-52. PubMed ID: 17315974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of bioavailable inhibitors of secretory phospholipase A2.
    Blanchard SG; Andrews RC; Brown PJ; Gan LS; Lee FW; Sinhababu AK; Wheeler TN
    Pharm Biotechnol; 1998; 11():445-63. PubMed ID: 9760691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico design and synthesis of piperazine-1-pyrrolidine-2,5-dione scaffold-based novel malic enzyme inhibitors.
    Zhang YJ; Wang Z; Sprous D; Nabioullin R
    Bioorg Med Chem Lett; 2006 Feb; 16(3):525-8. PubMed ID: 16288866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors.
    Jeong TS; Kim MJ; Yu H; Kim KS; Choi JK; Kim SS; Lee WS
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1525-7. PubMed ID: 15713421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
    Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
    ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipidic mimetics as inhibitors of pancreatic phospholipase A2.
    Nicolaou A; Kokotos G; Constantinou V; York J; Gibbons WA
    Biochem Soc Trans; 1995 Nov; 23(4):614S. PubMed ID: 8654799
    [No Abstract]   [Full Text] [Related]  

  • 17. High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX).
    Cha SS; Lee D; Adams J; Kurdyla JT; Jones CS; Marshall LA; Bolognese B; Abdel-Meguid SS; Oh BH
    J Med Chem; 1996 Sep; 39(20):3878-81. PubMed ID: 8831753
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis and evaluation of substrate-mimicking cytosolic phospholipase A2 inhibitors--reducing the lipophilicity of the arachidonyl chain isostere.
    Walters I; Bennion C; Connolly S; Croshaw PJ; Hardy K; Hartopp P; Jackson CG; King SJ; Lawrence L; Mete A; Murray D; Robinson DH; Stein L; Wells E; John Withnall W
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3645-9. PubMed ID: 15203135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling in the design of phospholipase A2 inhibitors.
    Ripka WC; Sipio WJ; Galbraith WG
    J Cell Biochem; 1989 Jul; 40(3):279-86. PubMed ID: 2777907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of secretory phospholipase A2. 2-Synthesis and structure-activity relationship studies of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one (PMS1062) derivatives specific for group II enzyme.
    Dong CZ; Ahamada-Himidi A; Plocki S; Aoun D; Touaibia M; Meddad-Bel Habich N; Huet J; Redeuilh C; Ombetta JE; Godfroid JJ; Massicot F; Heymans F
    Bioorg Med Chem; 2005 Mar; 13(6):1989-2007. PubMed ID: 15727853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.